Skip to content

Observational Study Regarding the Necessity of Inclusion of Foot Arch State Together With the Angiosome Theory Within the Wound, Ischemia and Foot Infection Classification (WIfI) to Enhance the Predictability of Wound Healing and Decision Making

Observational Study Regarding the Necessity of Inclusion of Foot Arch State Together With the Angiosome Theory Within the Wound, Ischemia and Foot Infection Classification (WIfI) to Enhance the Predictability of Wound Healing and Decision Making

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06542523
Enrollment
60
Registered
2024-08-07
Start date
2024-03-01
Completion date
2025-03-31
Last updated
2024-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Limb-Threatening Ischemia, Diabetic Foot, Vascular Diseases

Brief summary

This study aims to assess the complete healing or healing progress of foot ulcer within 1 year Where the patients will be classified according to foot arch state together with the angiosome theory and the WIFI clinical stage to reflect the the necessity of inclusion of foot arch state together with the angiosome theory within the WIFI classification to enhance the predictability of wound healing and decision making

Detailed description

Patients will be classified according to their WIFi stages into 3 groups and each group will be furtherly classified according to the patient's angiography of foot arch (whether by CT angiography or direct angiography) into: Type 1: patent foot arch Type 2: partially occluded foot arch which is divided into whether Type 2a: patent dorsal tributary of foot arch Type 2b: patent lateral tributary of foot arch Type 3: totally occluded foot arch is divided into whether. Type 3a: totally occluded foot arch with anterior tibial artery inflow. Type 3b: totally occluded foot arch with posterior tibial artery inflow. During follow-up assessments, wound is classified to be within: anterior tibial artery, posterior tibial artery or both territories. Wound healing states are often classified based on the progression of the healing process into each of the following categories such as: 1. Complete Healing: Wound closure with the restoration of tissue integrity and absence of signs of infection. 2. Partial Healing: Significant improvement but not complete closure; may involve reduction in wound size and improved tissue viability. 3. Worsening: Increase in wound size or signs of infection which may necessitates performing major amputation.

Interventions

None listed

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* diabetic foot in the form of gangrene, or a lower limb ulceration \>2 weeks duration.

Exclusion criteria

1. Age below 18 years old. 2. Critically ill patients 3. Patients with acute ischemia 4. patients with pure venous ulcer 5. patients with ulcer due to rheumatological disease 6. The patient has known sensitivity to heparin. 7. The patient has comorbid conditions that may limit their ability to comply with the follow-up requirements 8. The patient has an untreatable allergy to radiographic contrast material. 9. Patient refusing consent

Design outcomes

Primary

MeasureTime frameDescription
Complete Healing2,4,6 monthsWound closure with the restoration of tissue integrity and absence of signs of infection.
Partial Healing:2,4,6 monthssignificant improvement but not complete closure; may involve change in wound size and improved tissue viability.
Worsening2,4,6 monthschange in wound size or signs of infection which may necessitates performing major amputation. .

Secondary

MeasureTime frameDescription
Occurrence of Complicationwithin 30 days of the procedureRates of procedure- and device-related adverse events during revasularization

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026